Home
Inhibition of SARS-CoV-2-mediated thromboinflammation by CLEC2.Fc
Date: 2023-06-08
Immunothrombosis is the major cause of mortality and morbidity in acute COVID-19 and long COVID patients. However, the underlying mechanism is unclear. Dr. Hsieh’s research team unravel the mystery by showing that CLEC2 is the pattern recognition receptor for SARS CoV-2 spike protein, contributes for SARS CoV-2-induced NETosis and thromboinflammation, and injection of recombinant CLEC2.Fc inhibits immunothrombosis and alleviate visceral organ injury, suggesting targeting CLEC2 is promising to treat SARS-CoV-2-induced thrombosis in the future.
-
Link
Tag：
#COVID-19
